Intellia Therapeutics Inducement Grants Announcement
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading name in gene editing, has recently announced the approval of inducement awards aimed at attracting skilled professionals to its expanding team. These inducement grants are significant components of the company’s 2024 Inducement Plan, which is designed to further its strategic goals in developing CRISPR-based therapies.
Details of the Inducement Grants
The inducement grants consist of a series of non-qualified stock options, which represent ownership of 49,751 shares of Intellia's common stock. These options come with vesting timelines intended to enhance the experience of new hires. Specifically, 33% will vest by September 1, 2025, with the remaining shares vesting on a monthly basis until fully vested by September 1, 2027.
In addition, the company has granted time-based restricted stock units (RSUs) for 44,154 shares, with vesting scheduled over the years 2025, 2026, and 2027. There are also performance-based RSUs totaling 17,064 shares, which are tied to Intellia's stockholder returns and evaluated over a three-year period against comparable companies within the Nasdaq Biotechnology Index. Furthermore, an additional set of performance-based RSUs for 12,500 shares will depend on achieving specific developmental milestones.
Commitment to Employees
The successful vesting and earning of these equity awards depend on each employee’s continued engagement with Intellia. The company underscores the importance of maintaining service as an employee or other service provider throughout the vesting schedule, reinforcing a commitment to shared growth and success.
All grants issued fall outside of Intellia's stockholder-approved equity incentive plans, reflecting strategic decisions made by the board of directors, who established the 2024 Inducement Plan in June. The compensation committee is responsible for approving these awards, aligning with the company's strategy to strengthen its workforce in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a prominent clinical-stage gene editing company dedicated to revolutionizing medical treatments through innovative CRISPR-based therapies. Its cutting-edge in vivo programs enable precise editing of disease-causing genes within the human body, while its ex vivo programs focus on engineering human cells outside the body to tackle cancers and autoimmune disorders. Intellia combines deep scientific knowledge, technical expertise, and extensive clinical development experience to set industry benchmarks for this transformative class of medicine.
As the company aims to enhance its platforms, it is committed to refining editing and delivery technologies to unlock the full potential of gene editing, emphasizing its dedication to scientific and medical progress.
Frequently Asked Questions
What are the details of the inducement grants provided by Intellia?
The inducement grants include stock options for 49,751 shares, RSUs for 44,154 shares, and performance-based RSUs that depend on stockholder returns and developmental milestones.
When does the vesting of these options and RSUs occur?
One-third of the options and RSUs will vest on September 1, 2025, with additional vesting occurring monthly or annually until fully vested by September 1, 2027.
Why are these inducement grants significant for Intellia?
These grants aim to attract and retain talent by offering financial incentives, ensuring that employee interests align with those of the company and its shareholders.
How does Intellia Therapeutics utilize CRISPR technology?
Intellia leverages CRISPR technology to edit genes linked to diseases both within the body and externally, with the goal of treating various conditions including cancer and autoimmune diseases.
Who can be contacted for more information regarding Intellia's developments?
For more information, investors can reach out to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications, or Lina Li, Senior Director, at their respective emails.
